Gerald Clarke | 08/08/2013
As part of our Future Pharma series, Pharma IQ is examining the promise held by synthetic biology. Our editor spoke to Professor Paul Freemont Chair in Protein Crystallography and Co-Founder and Co-Director of the EPSRC Centre for Synthetic Biology and Innovation at Imperial College London. Professor Freemont Describes the current technical challenges which this exciting field is seeking to overcome, some of the most exciting projects and how synthetic biology will change the pharma industry....
To continue reading this story Click Here
RECOMMENDED
MSD announces Phase III data on investigational treatment to lower LDL Cholesterol (LDL-C)
2025-11-17
AI for Pharma & Healthcare 2025
2025-06-18
Upcoming Events
SmartLab Exchange USA
April 20-21, 2026
The Logan, Philadelphia, USA
Register Now |
View Agenda |
Learn More